Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Must Reads In Lung Cancer
Lung Cancer for January/February 2018
Cochrane on Vaccine-Based Immunotherapy for NSCLC, Cochrane; 2017 Dec 16; Zhu, Li, Tiselius, et al
Lung Cancer for September/October 2017
Durvalumab Post-Chemoradiotherapy in NSCLC Assessed, N Engl J Med; ePub 2017 Sep 8; Antonia, et al
Cochrane on Heparin Impact in People with Cancer , Cochrane; 2017 Sep 11; Akl, Kahale, et al
FDA Approves First Biosimilar to Treat Cancer, FDA news release; 2017 Sep 14
Lung Cancer for July/August 2017
ASCO Updates Stage IV NSCLC Treatment Guideline, J Clin Oncol; ePub 2017 Aug 14; Hanna, et al
HER2 Mutations in Lung Adenocarcinomas Evaluated, Cancer; ePub 2017 Jul 25; Pillai, Behera, et al
Fat Intake and Lung Cancer Risk Evaluated, J Clin Oncol; ePub 2017 Jul 25; Yang, Yu, et al
Lung Cancer for May/June 2017
Cochrane Reviews Exercise Training Before Lung Surgery, Cochrane; 2017 Jun 7; Cavalheri, Granger
Chemoradiotherapy Outcomes in Patients with NSCLC, J Clin Oncol; 2017 May 11; Stinchcombe, et al
FDA Broadens Ceritinib Indication, FDA news release; 2017 May 26
FDA Approves Tool to Identify ALK-Positive NSCLC Patients, Roche news release; 2017 Jun 1
Keytruda + Pem/Carbo Approved for Lung Cancer, Merck news release; 2017 May 10
Lung Cancer for March/April 2017
Tagrisso Approved for Non-Small Cell Lung Cancer, FDA news release; 2017 Mar 30
Cardiac Events After RT in Lung Cancer Patients, J Clin Oncol; ePub 2017 Mar 16; Dess, Sun, et al
Radiation Therapy After R0 Resection for NSCLC , Ann Surg Oncol; ePub 2017 Feb 2; Pezzi, et al
